



STD-AIDS-2014



Clinical and immunologic pattern of PLHIV lost from HIV care before initiated Antiretroviral treatment within an HIV Program in Tanzania

Aisa N Muya, MD, MPH Management and Development for Health (MDH)

Co-authors: Expeditho Mtisi, Lameck Machumi, Guerino Chalamilla



LIKENSEED HOLITI HEV HOLI

HIV/AIDS in Tanzania

- HIV prevalence of 5.1%*;
- Estimated number of PLHIV- 2.2 million*
- Enrolled for HIV care: 1.4 million by 2014**
- Initiated ART: 928,484**
- Current on ART: 560,262**
- MDH supported HIV care and treatment program:
 - Enrolled: 158,520 PLHIV***
 - Initiated ART: 118,649***
 - Current on ART: 72,977***

*The Tanzania HIV/AIDS and Malaria Indicator Survey (THMIS)2012



** NACP report June 2014 *** MDH report June 2014



Retention on HIV care



- Early ART initiation improves survival and quality of life of PLHIV (Cohen, N Eng Med 2011)
- Retention of patients on care before ART initiation is still a major challenge in SSA, including Tanzania(Fox MP, Trop Med Int Health 2010)
- In MDH supported program in Tanzania,
 52.7% of enrolled patients were lost to follow up before initiated ART (Sept 2012)







- Advanced clinical and immunological HIV disease is associated with early mortality (Chalamilla et al, J Int Assoc Physicians AIDS Care (Chic). 2012
- Understanding clinical and immunological patterns associated with patients' LTFU before ART initiation is critical

Study Objective:

 To study the clinical and immunological patterns among patients who have defaulted from HIV care before initiated ART





Methods

- Survival analysis of HIV-infected patients enrolled between Oct 2004 – Sept 2012 from the 80 facilities in DSM,
- Analysis cohort: The 25,433 PLHIV who were not initiated ART
- Event outcome was lost to follow up (LTFU)
- LTFU was defined as:
 - missing clinic visit for more than 180 consecutive days after the last scheduled appointment date among patients on HIV care and monitoring





Methods - Analysis

- Data were analyzed using SAS version 9.3
- In Univariate and multivariate analysis, Cox proportional hazard regression model was employed to identify clinical and immunological risk factors.
- Variables with p value <0.2 in univariate analysis were included in the multivariate model
- Kaplan Meier plots were used to determine the probability of loss to follow up









- Among 25,433 patients enrolled to HIV care:
 - 13,395 (52.7%) were lost before ART initiation
 - Females were 77%
 - -Median age: 35 years (IQR: 29- 42 years)
 - Median CD4+ cell count: 218 cells/mm³
 (IQR: 89 -390 cells/mm³)

Table 1: Basic Characteristics at Enrollment of patients not initiated ART between Oct 2004 –Sep 2012 (N= 25.433)



Variable	N	Percentage (%)	Variable	N	Percentage (%)
Sex			Married		
Male	6,104	34.0	Νο	14,573	57.3
Female	19,329	76.0	Yes	10,860	42.7
Age groups, years			WHO stage:		
<30	10,046	39.5	I	10,529	41.4
30 - <40	9,894	38.9	II	5,926	23.3
40 - <50	3,840	15.1	III	6,511	25.6
50+	1,653	6.5	IV	2,467	9.7
BMI , kg/m²			CD4 count, cells/mm ³		
<18.5	7,579	29.8	<200	12,183	47.9
18.5 - <25	11,343	44.6	200 - <350	3,535	13.9
25 - <30	4,400	17.3	350+	9,715	38.2
30 +	2,111	8.3			9







- Significant increased risk for LTFU was found among patients with:
 - -CD4 <200 cells/mm³ (HR: 2.10, 95% CI 2.07 – 2.22, p<0.0001);</p>
 - WHO clinical stage IV (HR: 1.26, 95%CI 1.14 – 1.39, p<0.0001)</p>
 - BMI ratio <18.5 kg/ m² (HR: 1.16, 95% CI 1.07-1.25, p=0.03)



Table 2: Univariate and Multivariate for LTFU for Patients enrolled in care and not initiated ART (N = 25,433 patients with 13,395 events)



Variable	Univariate HR (95% Cl)	P for Trend	Multivariate HR (95% CI)	P for Trend
Sex				
Male	1.26 (1.20 – 1.33)	< 0.0001	1.06 (1.01 – 1.14)	0.04
Female	Reference		Reference	
Age		< 0.0001		0.1
<30	0.35 (0.33 – 0.36)		0.42 (0.40 – 0.45)	
30 - <40	Reference		Reference	
40 - <50	1.04 (0.97 – 1.12)		1.04 (0.97 – 1.12)	
50+	1.09 (0.99 – 1.20)		1.09 (0.99 – 1.20)	
BMI group: kg/m ²		<0.0001		0.03
<18.5	1.86 (1.76-1.93)	\langle	1.16 (1.07 -1.25)	
18.5 - <25	Reference		Reference	
25 - <30	0.84 (0.80-0.88)		0.92 (0.86-0.97)	
30 +	0.72 (0.67- 0.76)		0.78 (0.71-0.84)	11



Table 2: Univariate and Multivariate for LTFU for Patients enrolled in care and not initiated ART (N = 25,433 patients with 13,395 events)



Variable	Univariate HR (95% CI)	P for Trend	Multivariate HR (95% CI)	P for Trend
CD4 count, cells/mm ³		<0.0001		<0.0001
<200	2.60 (2.53 – 2.65)	(2.10 (2.07 – 2.22)	
200 - <350	1.30 (1.23 – 1.86)		1.26 (1.20 – 1.33)	
350+	Reference		Reference	
WHO stage:		<0.0001		<0.0001
I	Reference		Reference	
II	1.04 (0.99 – 1.09)		0.96 (0.91 – 1.02)	
III	1.73 (1.66 – 1.81)		1.18 (1.11 – 1.26)	
IV	2.61 (2.48 – 2.75)	(1.26 (1.14 – 1.39)	
Married		<0.0001		0.001
Νο	Reference		Reference	
Yes	0.88 (0.84- 0.92)		0.92 (0.88- 0.97)	

Kaplan Meier probability of LTFU by Clinical stage and CD4 count







Conclusion



- Patients with advance HIV/AIDS disease have significant increased risk of being LTFU
- The identified clinical and immunological pattern among LTFU patients correspond to the risk factors associated with HIV/AIDS mortality identified in other studies (Chalamilla et al, 2012)
- This suggests possibility of AIDS mortality among the LTFU patients in programs that do not have efficient patient tracking system



Recommendations



- Special adherence counseling targeting patients with advance HIV disease in tandem with early ART initiation may reduce LTFU
- HIV Programs to design more effective patient tracking systems targeting patients in HIV care awaiting ART initiation.
- Further studies on effective models to improve patient retention in HIV care and treatment





Acknowledgements

- The govt of Tanzania through Ministry of Health and Social welfare
- The Dar es Salaam regional secretariat and its municipal councils health management teams
- Management and Development for Health staff
- This study has been supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through Centers for Disease Control and Prevention under the terms of SHAPE Project Award # GH11-112703CONT13





THANK YOU

AHSANTENI SANA